How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
33
IPHA Quote, Financials, Valuation and Earnings
Last price:
$1.77
Seasonality move
:
-10.69%
Day range:
$1.74 - $1.85
52-week range:
$1.63 - $2.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.99x
P/B ratio:
20.75x
Volume:
8.7K
Avg. volume:
24.8K
1-year change:
1.14%
Market cap:
$166.8M
Revenue:
$13.7M
EPS (TTM):
-$0.60
Analysts' Opinion
-
Consensus RatingInnate Pharma SA has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.75, Innate Pharma SA has an estimated upside of 223.03% from its current price of $1.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.78.
Fair Value
-
According to the consensus of 4 analysts, Innate Pharma SA has 223.03% upside to fair value with a price target of $5.75 per share.
IPHA vs. S&P 500
-
Over the past 5 trading days, Innate Pharma SA has overperformed the S&P 500 by 1.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Innate Pharma SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innate Pharma SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Innate Pharma SA reported revenues of --.
Earnings Growth
-
Innate Pharma SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Innate Pharma SA reported earnings per share of --.
Enterprise value:
138.6M
EV / Invested capital:
--
Price / LTM sales:
22.99x
EV / EBIT:
0.37x
EV / Revenue:
10.23x
PEG ratio (5yr expected):
0.03x
EV / Free cash flow:
-17.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.32x
Gross Profit (TTM):
--
Return On Assets:
-18.89%
Net Income Margin (TTM):
-768.79%
Return On Equity:
-72.79%
Return On Invested Capital:
-39.78%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-04-30 | 2020-04-30 | 2021-04-30 | 2020-04-30 | 2021-04-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $262.4M | $261.1M | |
| Gross Profit | -- | -- | -- | $98.7M | $100.7M | |
| Operating Income | -- | -- | -- | $46.3M | $51.4M | |
| EBITDA | -- | -- | -- | $55.1M | $59M | |
| Diluted EPS | -- | -- | -- | $0.38 | $0.42 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $154.3M | $179.5M | $157M | $119.6M | -- | |
| Total Assets | $316.8M | $292.9M | $216.3M | $162.4M | -- | |
| Current Liabilities | $50.7M | $76.8M | $40.9M | $41M | -- | |
| Total Liabilities | $157.9M | $171.4M | $153.4M | $131.5M | -- | |
| Total Equity | $158.9M | $121.5M | $62.9M | $30.9M | -- | |
| Total Debt | $19.6M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2020-03-31 | 2021-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $22.5B | $4B | |
| Cash From Investing | -- | -- | -- | $5B | $14.2M | |
| Cash From Financing | -- | -- | -- | $492.2M | -$789K | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
IPHA
Sector
Market Cap
$166.8M
$25.9M
Price % of 52-Week High
67.68%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-11.59%
-1.66%
1-Year Price Total Return
1.14%
-18.99%
Beta (5-Year)
-0.018
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.77
200-day SMA
Sell
Level
$1.98
Bollinger Bands (100)
Sell
Level
1.77 - 2.05
Chaikin Money Flow
Sell
Level
-10.6K
20-day SMA
Buy
Level
$1.76
Relative Strength Index (RSI14)
Sell
Level
49.36
ADX Line
Buy
Level
8.87
Williams %R
Neutral
Level
-50
50-day SMA
Sell
Level
$1.81
MACD (12, 26)
Buy
Level
0.40
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
8.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.142)
Sell
CA Score
(Annual)
Level (-3.6056)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (4.8368)
Sell
Piotroski F Score
(Annual)
Level (2)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Stock Forecast FAQ
In the current month, IPHA has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IPHA average analyst price target in the past 3 months is $5.75.
-
Where Will Innate Pharma SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innate Pharma SA share price will rise to $5.75 per share over the next 12 months.
-
What Do Analysts Say About Innate Pharma SA?
Analysts are divided on their view about Innate Pharma SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innate Pharma SA is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Innate Pharma SA's Price Target?
The price target for Innate Pharma SA over the next 1-year time period is forecast to be $5.75 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IPHA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innate Pharma SA is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IPHA?
You can purchase shares of Innate Pharma SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innate Pharma SA shares.
-
What Is The Innate Pharma SA Share Price Today?
Innate Pharma SA was last trading at $1.77 per share. This represents the most recent stock quote for Innate Pharma SA. Yesterday, Innate Pharma SA closed at $1.78 per share.
-
How To Buy Innate Pharma SA Stock Online?
In order to purchase Innate Pharma SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IPHA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IPHA
Sector
P/E ratio
--
23.82x
PEG ratio
0.03x
-0.01x
P/B ratio
20.75x
1.83x
Price / LTM sales
22.99x
1.56x
Growth Metrics
IPHA
Sector
Revenue growth
--
4.18%
Earnings growth
--
9.66%
Revenue (5-year growth)
-29.28%
6.28%
Earnings forecast
--
-$0.18
Profitability
IPHA
Sector
Profitability FY 2024
--
$3.1M
Return on invested capital
-39.78%
-32.89%
Return on assets
-18.89%
-29.56%
Return on equity
-72.79%
-38.66%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
IPHA
Sector
Total cash
$98.4M
$25.2M
Short term investments
$15M
$25.1M
Total assets
$115M
$73M
Long term debt
--
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
48
SANM alert for Jan 29
Sanmina Corp. [SANM] is up 6.61% over the past day.
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is up 20.87% over the past day.
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is up 20.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
